Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
|Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD
Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment
WARREN, N.J., May 22, 2017 (GLOBE... |
Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update
|WARREN, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2017.
“Overall progress in our ongoing clinical programs has been encouraging and I am pleased with data recently reported in both PAH and in pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). We look forward to the presentation o... |
Bellerophon Announces $3.0 Million Registered Direct Offering
|WARREN, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement with a single institutional investor for an offering of shares of its common stock with gross proceeds of $3.0 million in a registered direct offering. The closing of the offering is expected to take place on or about May 15, 2017, subject to the satisfaction of customary closing conditions.
In ... |